Cashu | News | ONC

HomeWatchlistNewsSignalsPicks

DJI

-0.48%

SPX

-0.32%

IXIC

-0.03%

FTSE

-0.09%

N225

+1.03%

AXJO

+0.51%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Latest BeiGene News

BeOne Medicines Stock Gains Momentum With Early-Stage Trial Success For Pretreated Lymphoma Patients

Feature Image for interests on Biotech, Health Care, Healthcare, Large Cap from benzinga.com

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

Feature Image for interests on Biotech, Health Care, Healthcare, Large Cap from benzinga.com

A Glimpse of BeiGene's Earnings Potential

about 1 month ago

Deep Dive Into BeOne Medicines Stock: Analyst Perspectives (9 Ratings)

about 2 months ago

Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings Beat

Feature Image for interests on Amgn, Benzinga, Biotech, Briefs from benzinga.com

nference and BeiGene Collaborate to Drive New B-Cell Cancer Research

Feature Image for interests on Artificial Intelligence, Healthcare, Licensing, Medical Equipment from prnewswire.com

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Netflix, Bank of America, Meta, Reddit, Microsoft & more

Feature Image for interests on Basic Materials, Breaking News: Investing, Breaking News: Markets, Communication Services from cnbc.com

businesswire.com

Riassunto: BeiGene offre un aggiornamento sul programma di sviluppo clinico Ociperlimab (BGB-A1217)

businesswire.com

Riassunto: BeiGene offre un aggiornamento sul programma di sviluppo clinico Ociperlimab (BGB-A1217)

businesswire.com

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

Stocks

Health Care

onc

BeiGene

SHANGHAI STOCK EXCHANGE: ONC

+23.16 (+7.27%)

341.89

USD

At close at Sep 05, 20:41 UTC

Latest Cashu News

BeOne Medicines Reports Promising Results for Sonrotoclax in Relapsed Mantle Cell Lymphoma

BeiGene Advances Sonrotoclax Research for Relapsed/Refractory Mantle Cell Lymphoma Treatment

BeiGene: BeOne Medicines Sells Royalty Rights to Capitalize on Oncology Market Potential